We offer FREE SHIPPPING on all orders!
We offer FREE SHIPPPING on all orders!
| THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for invitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic. |
CJC-1295 No DAC is an experimental growth hormone-releasing hormone analogue designed to stimulate the body's own pituitary release of growth hormone.
Despite the common commercial name, "CJC-1295 No DAC" is generally used to refer to Modified GRF 1-29, also known as Mod GRF 1-29. This distinction is important because true CJC-1295 with DAC is a substantially longer-acting compound.
Its primary research areas include:
Growth hormone release
IGF-1 signaling
Body composition
Muscle recovery
Fat metabolism
Sleep and recovery
Tissue repair
Exercise recovery
Age-related changes in growth hormone secretion
A vial labeled "CJC-1295 No DAC 10mg" represents a total of 10 milligrams of peptide in the vial. It does not mean that 10mg is an established or appropriate single human dose.
CJC-1295 No DAC is a synthetic peptide related to growth hormone-releasing hormone, or GHRH.
Natural GHRH is produced by the hypothalamus.
Its primary function is to signal the pituitary gland to release growth hormone.
The simplified pathway is:
Hypothalamus
GHRH
Pituitary gland
Growth hormone
Liver and other tissues
IGF-1 and additional downstream effects
CJC-1295 No DAC attempts to stimulate this same physiological pathway.
DAC stands for:
Drug Affinity Complex
The DAC modification was developed to dramatically extend the circulating life of CJC-1295 by allowing it to bind to albumin in the bloodstream.
CJC-1295 with DAC is therefore long acting.
CJC-1295 No DAC does not contain this albumin-binding DAC modification.
As a result, it is considerably shorter acting.
This is the most important distinction.
CJC-1295 No DAC:
Short acting
Commonly identified with Mod GRF 1-29
Produces relatively short GH stimulation
More closely follows pulsatile GH physiology
Does not use the DAC albumin-binding modification
CJC-1295 with DAC:
Long acting
Contains Drug Affinity Complex technology
Binds circulating albumin
Produces prolonged GH and IGF-1 stimulation
Has a dramatically longer biological duration
They should not be treated as interchangeable products.
Technically, the terminology used by peptide suppliers can be confusing.
The compound commonly sold as:
"CJC-1295 No DAC"
is generally Modified GRF 1-29.
True CJC-1295 was developed with the DAC modification.
Therefore, a scientifically more precise name for the No DAC version is:
Modified GRF 1-29
or:
Mod GRF 1-29
However, "CJC-1295 No DAC" has become extremely common commercial terminology.
Modified GRF 1-29 is a synthetic analogue of the first 29 amino acids of GHRH.
The first 29 amino acids contain the biologically active region required for growth hormone-releasing activity.
Several amino acids are modified to make the peptide more resistant to enzymatic degradation.
This is important because natural GHRH 1-29 is rapidly broken down.
Natural GHRH has a very short circulating life.
Enzymes can rapidly degrade it.
The goal of Mod GRF 1-29 is to preserve GHRH receptor activity while making the molecule more resistant to degradation.
The simplified concept is:
Natural GHRH
Very rapid degradation
Modify selected amino acids
Greater stability
Longer opportunity to stimulate GHRH receptors
CJC-1295 No DAC binds to GHRH receptors on somatotroph cells in the anterior pituitary.
This stimulates growth hormone secretion.
The pathway is:
CJC-1295 No DAC
GHRH receptor
Pituitary somatotroph
Growth hormone release
GH receptor signaling
Potential increase in IGF-1
Metabolic and tissue effects
Growth hormone, or GH, is produced by the anterior pituitary.
GH influences:
Growth
Fat metabolism
Protein metabolism
Bone
Connective tissue
Muscle maintenance
Glucose metabolism
Recovery
IGF-1 production
GH secretion naturally occurs in pulses rather than remaining constant throughout the day.
Natural GH secretion is highly pulsatile.
Large pulses frequently occur:
During deep sleep
After certain types of exercise
During fasting
In response to GHRH
Between pulses, GH concentrations can fall dramatically.
This pulsatile physiology is one reason short-acting GHRH analogues are scientifically interesting.
Because CJC-1295 No DAC is relatively short acting, it can produce a more defined period of GHRH receptor stimulation.
CJC-1295 DAC provides prolonged stimulation.
This creates an important conceptual difference:
No DAC = shorter GHRH signaling.
DAC = prolonged GHRH signaling.
It does not automatically mean one is superior.
They simply produce different pharmacological profiles.
Growth hormone stimulates production of insulin-like growth factor 1, or IGF-1.
The liver is a major source of circulating IGF-1, although many tissues also produce IGF-1 locally.
The pathway is:
CJC-1295 No DAC
Growth hormone
IGF-1
IGF-1 participates in:
Protein synthesis
Tissue growth
Bone metabolism
Muscle maintenance
Cellular repair
Connective-tissue biology
No.
This is an important distinction.
CJC-1295 No DAC does not supply HGH directly.
It stimulates the pituitary to release the body's own growth hormone.
HGH:
Is growth hormone itself
Directly increases circulating GH
Does not require pituitary release
Produces pharmacological GH exposure
CJC-1295 No DAC:
Is a GHRH analogue
Stimulates endogenous GH release
Requires a functioning pituitary
Works upstream of growth hormone
The distinction is:
HGH replaces or supplies GH.
CJC-1295 No DAC stimulates GH secretion.
CJC-1295 No DAC is not a direct anabolic compound like testosterone.
Potential muscle-related effects would occur indirectly through:
Growth hormone
IGF-1
Recovery
Protein metabolism
Connective-tissue support
This makes its mechanism fundamentally different from anabolic steroids.
There is insufficient controlled evidence showing dramatic muscle growth from CJC-1295 No DAC in healthy trained individuals.
Bodybuilding interest generally centers on potential effects involving:
Recovery
GH secretion
IGF-1
Body composition
Fat metabolism
Sleep quality
Connective tissue
However, increased GH secretion should not automatically be equated with major muscle hypertrophy.
GH has substantially different anabolic effects from testosterone.
Testosterone primarily promotes muscle growth through androgen receptor signaling.
Growth hormone primarily influences:
IGF-1
Connective tissue
Collagen
Fat metabolism
Fluid balance
Tissue growth
They are completely different endocrine systems.
Growth hormone participates in lipolysis.
Lipolysis is the process through which stored triglycerides are mobilized into:
Free fatty acids
Glycerol
Therefore, increasing GH can theoretically influence fat metabolism.
However, CJC-1295 No DAC is not an approved obesity treatment.
Not primarily.
It does not work through the major appetite-regulating mechanisms associated with:
GLP-1
GIP
Amylin
Therefore, it is very different from compounds such as cagrilintide, semaglutide, or tirzepatide.
GH signaling can influence visceral adipose tissue.
However, CJC-1295 No DAC does not have the same clinical evidence for visceral-fat reduction as Tesamorelin has in adults with HIV-associated lipodystrophy.
The two should not be treated as equivalent.
Both act through the GHRH receptor.
CJC-1295 No DAC:
Modified GHRH 1-29 analogue
Short acting
Experimental
Common in research and performance communities
No FDA-approved therapeutic indication
Tesamorelin:
Modified full-length GHRH analogue
Pharmaceutical development
Strong human clinical evidence
FDA-approved for reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy
Tesamorelin has a substantially stronger clinical evidence base.
These peptides are closely related.
Sermorelin:
GHRH 1-29
Short acting
Mimics the active region of natural GHRH
CJC-1295 No DAC or Mod GRF 1-29:
Modified GHRH 1-29
Contains amino-acid substitutions designed to resist enzymatic degradation
Generally considered more degradation-resistant than unmodified Sermorelin
Both stimulate the same primary receptor.
This is another important comparison.
CJC-1295 No DAC:
GHRH receptor agonist
Stimulates GH through the GHRH pathway
Ipamorelin:
Ghrelin receptor agonist
Activates GHS-R1a
Stimulates GH through the growth hormone secretagogue pathway
They therefore stimulate GH through different receptors.
The biological rationale is receptor synergy.
CJC-1295 No DAC activates:
GHRH receptor.
Ipamorelin activates:
GHS-R1a.
Both pathways converge on pituitary growth hormone release.
The simplified concept is:
CJC-1295 No DAC
plus
Ipamorelin
Two different pituitary signaling pathways
Potentially larger GH pulse
This receptor interaction is biologically plausible, but popular research protocols should not be confused with FDA-established treatment regimens.
GHRP-2 is another ghrelin-receptor growth hormone secretagogue.
GHRP-2 can strongly stimulate GH but may also influence:
Appetite
Prolactin
Cortisol
CJC-1295 No DAC acts through the GHRH receptor instead.
GHRP-6 is known particularly for strong appetite stimulation.
This occurs through ghrelin receptor activity.
CJC-1295 No DAC does not primarily activate the ghrelin receptor and therefore should not produce the same characteristic hunger response.
Growth hormone and IGF-1 participate in several processes relevant to recovery, including:
Collagen synthesis
Connective-tissue metabolism
Protein turnover
Cellular repair
Bone metabolism
This creates a plausible biological basis for recovery research.
However, CJC-1295 No DAC is not an approved sports-injury treatment.
Growth hormone and IGF-1 can influence collagen-producing cells and connective tissue.
This makes tendon research biologically interesting.
However, there is no evidence that CJC-1295 No DAC reliably repairs a torn human tendon.
The same limitation applies to ligaments.
Potential improvement in collagen metabolism does not mean that severe structural injuries can regenerate without appropriate orthopedic treatment.
Growth hormone signaling can influence collagen synthesis.
Collagen is a major structural protein found in:
Tendons
Ligaments
Skin
Cartilage
Bone
Connective tissue
Therefore, GH-related compounds are frequently discussed in connective-tissue research.
The GH and IGF-1 axis plays an important role in:
Bone development
Bone remodeling
Osteoblast function
Skeletal maintenance
However, CJC-1295 No DAC is not an established osteoporosis medication.
Growth hormone secretion is strongly connected to sleep.
One of the largest natural GH pulses commonly occurs during slow-wave sleep.
Some users of GH-secretagogue compounds report:
Deeper sleep
Improved recovery
More vivid dreams
These reports should not be interpreted as evidence that CJC-1295 No DAC is a sleep medication.
Deep slow-wave sleep is strongly associated with natural GH secretion.
Therefore, the relationship works in both directions conceptually:
Sleep physiology influences GH secretion.
GH-related signaling may also interact with recovery and sleep-related physiology.
CJC-1295 No DAC should not replace treatment for an actual sleep disorder.
Growth hormone secretion generally declines with age.
This has led to widespread interest in GHRH analogues for "anti-aging."
However:
Restoring a youthful-looking laboratory value
does not automatically equal
reversing aging.
There is no evidence that CJC-1295 No DAC extends human lifespan.
GH and IGF-1 influence:
Collagen
Connective tissue
Skin thickness
Tissue turnover
This creates theoretical interest in skin quality.
However, CJC-1295 No DAC is not an established dermatological anti-aging treatment.
There is insufficient evidence that CJC-1295 No DAC reliably promotes scalp hair growth.
Hair biology involves numerous pathways, including:
Androgens
Genetics
Follicular signaling
Blood supply
Inflammation
Increasing GH does not automatically reverse common pattern hair loss.
Some people associate GH optimization with improved:
Energy
Recovery
Exercise tolerance
General well-being
Others may experience fatigue.
CJC-1295 No DAC should not be considered a stimulant.
Potential areas of athletic interest include:
Recovery
Body composition
Connective tissue
Sleep
GH signaling
However, there is insufficient evidence showing that CJC-1295 No DAC reliably improves strength, speed, endurance, or competitive performance in healthy athletes.
These compounds have very different mechanisms.
CJC-1295 No DAC:
GHRH receptor
GH release
IGF-1 pathway
BPC-157:
Experimental tissue-protection pathways
Angiogenesis
Fibroblast migration
Gastrointestinal and connective-tissue research
They should not be treated as interchangeable.
TB-500-related research involves:
Actin
Cell migration
Angiogenesis
Tissue repair
CJC-1295 No DAC works through the endocrine GH axis.
Again, the mechanisms are completely different.
AOD-9604 is derived from the C-terminal region of HGH and was designed primarily around fat metabolism.
CJC-1295 No DAC stimulates endogenous GH secretion.
Therefore:
AOD-9604 = HGH-derived metabolic fragment.
CJC-1295 No DAC = GHRH analogue.
CJC-1295 No DAC does not primarily target the reproductive hormone axis.
It is not designed to directly stimulate:
GnRH
LH
FSH
Testosterone
Any changes in testosterone would be secondary rather than its primary mechanism.
It is not known to suppress natural testosterone production in the manner of anabolic steroids.
Traditional steroid-style post-cycle therapy is not generally associated with CJC-1295 No DAC.
It does not primarily suppress the hypothalamic-pituitary-gonadal axis.
This is more complicated.
The GH axis contains natural negative-feedback mechanisms.
As GH and IGF-1 increase, the body can modify:
GHRH signaling
Somatostatin signaling
Pituitary GH secretion
CJC-1295 No DAC works within this regulated endocrine system.
Its effects should not be described as simply "adding GH without affecting natural regulation."
Somatostatin is one of the body's major inhibitors of growth hormone release.
Natural GH secretion depends partly on the balance between:
GHRH = stimulates GH.
Somatostatin = inhibits GH.
Ghrelin-related signaling = stimulates GH.
This explains why GH responses can vary considerably depending on physiological conditions.
Growth hormone can reduce insulin sensitivity when chronically elevated.
Potential concerns with excessive GH signaling include:
Higher fasting glucose
Reduced insulin sensitivity
Increased insulin requirements
Metabolic stress
The magnitude of this effect with experimental CJC-1295 No DAC use is not well characterized.
Because CJC-1295 No DAC can increase GH signaling, glucose metabolism remains relevant.
Long-term excessive GH activity is not metabolically harmless.
People sometimes focus only on potential fat-loss effects while overlooking the fact that GH can oppose insulin action.
Growth hormone-related compounds can potentially cause:
Water retention
Swelling
Puffy appearance
This can occur through changes in fluid and sodium balance.
Excessive GH-related signaling can contribute to:
Tingling
Numbness
Hand swelling
Carpal-tunnel-like symptoms
These effects are better established with significant GH exposure but remain biologically relevant to GH-stimulating compounds.
A vial labeled:
"CJC-1295 No DAC 10mg"
means the supplier represents the vial as containing a total of 10 milligrams of peptide.
The 10mg represents total vial content.
It should not be interpreted as a single established administration amount.
There is no FDA-approved CJC-1295 No DAC regimen for bodybuilding, anti-aging, fat loss, recovery, or general GH optimization.
Research suppliers commonly sell CJC-1295 No DAC as lyophilized powder.
The fact that a product is packaged in an injectable-style vial does not establish that it is an approved injectable medication.
Important quality considerations include:
Correct peptide identity
Correct sequence
Sterility
Endotoxin levels
Vial quantity
Chemical purity
Stability
Manufacturing quality
CJC-1295 No DAC is short acting compared with the DAC version.
Modified GRF 1-29 was designed to resist rapid enzymatic degradation better than unmodified GHRH 1-29.
However, it still produces a much shorter exposure profile than CJC-1295 with DAC.
This short duration is one of the defining characteristics of the No DAC version.
The DAC modification allows the peptide to bind to circulating albumin.
Albumin is a highly abundant blood protein with a long circulating life.
Binding to albumin dramatically slows peptide clearance.
Without DAC, this prolonged albumin-binding effect is absent.
This is one of the main theoretical attractions of the No DAC form.
Rather than producing prolonged stimulation, a short-acting GHRH analogue can produce a more discrete GH secretory event.
This is closer conceptually to the body's natural pulsatile endocrine pattern.
However, "more physiological" does not automatically mean clinically superior or safer.
Potential adverse effects associated with GHRH and GH-related signaling can include:
Headache
Flushing
Dizziness
Fatigue
Nausea
Injection-site irritation
Water retention
Swelling
Tingling or numbness
Increased hunger in some individuals
Changes in blood glucose
Reduced insulin sensitivity
The true adverse-event frequency for research-grade CJC-1295 No DAC is not well established.
Long-term safety in healthy people using CJC-1295 No DAC for performance, bodybuilding, or anti-aging has not been established.
Important areas of uncertainty include:
Chronic IGF-1 elevation
Glucose metabolism
Insulin resistance
Fluid retention
Cardiovascular effects
Tissue growth
Long-term pituitary signaling
GH and IGF-1 participate in cellular growth and survival.
This creates a legitimate theoretical concern when manipulating the GH/IGF-1 axis in someone with an existing malignancy or abnormal cell growth.
This does not establish that CJC-1295 No DAC causes cancer.
It also does not establish that it is harmless in every cancer-related context.
Acromegaly is caused by chronic pathological excess growth hormone, usually from a pituitary tumor.
It can cause:
Enlarged hands and feet
Facial changes
Soft-tissue growth
Joint problems
Cardiovascular disease
Insulin resistance
Normal experimental exposure to a GHRH analogue is not equivalent to acromegaly.
However, acromegaly demonstrates why chronically excessive GH and IGF-1 signaling is not desirable.
Research peptide quality can vary.
Potential problems include:
Wrong peptide
Incorrect sequence
Incorrect vial quantity
Degradation
Chemical impurities
Bacterial contamination
Endotoxins
Poor sterility
This is particularly important with CJC products because commercial naming can already be confusing.
A product labeled "CJC-1295" may refer to:
CJC-1295 with DAC
CJC-1295 No DAC
Mod GRF 1-29
Those are not pharmacokinetically equivalent.
HPLC can help assess chemical purity.
Mass spectrometry can help confirm molecular identity.
However, 99 percent analytical purity does not automatically establish:
Sterility
Endotoxin level
Exact vial quantity
Correct peptide sequence
Correct DAC status
Pharmaceutical manufacturing quality
Human safety
These require separate verification.
Research Use Only, or RUO, means that a product is marketed for laboratory or analytical research rather than as an approved medication for human treatment.
An RUO CJC-1295 No DAC vial should not be treated as an approved HGH therapy.
No.
CJC-1295 No DAC is not FDA approved for:
Growth hormone optimization
Bodybuilding
Muscle growth
Fat loss
Anti-aging
Athletic recovery
Sleep enhancement
Injury healing
General wellness
There is no FDA-approved human dosing protocol for CJC-1295 No DAC.
GHRH receptor biology:
Strong.
GHRH stimulation of growth hormone:
Strong.
Modified GHRH analogues stimulating GH:
Biologically well supported.
Growth hormone effects on IGF-1:
Strong.
Growth hormone effects on lipolysis:
Strong.
Growth hormone involvement in connective tissue:
Strong.
CJC-1295 No DAC for bodybuilding:
Not established.
CJC-1295 No DAC for significant muscle growth:
Not established.
CJC-1295 No DAC for obesity:
Not established.
CJC-1295 No DAC for injury healing:
Not established.
CJC-1295 No DAC for anti-aging:
Not established.
CJC-1295 No DAC for lifespan extension:
Not established.
Long-term healthy-human safety:
Insufficiently characterized.
The biggest potential advantage is its short-acting stimulation of the body's endogenous growth hormone system.
Rather than directly supplying HGH, the theoretical pathway is:
CJC-1295 No DAC
GHRH receptor
Pituitary stimulation
Endogenous GH pulse
IGF-1 and downstream GH effects
Natural endocrine feedback remains involved in this process.
Its short duration also distinguishes it from CJC-1295 with DAC and makes pulsatile GH stimulation the central concept behind the compound.
The biggest limitation is the gap between established GH physiology and claims made for CJC-1295 No DAC in healthy people.
It is well established that:
GHRH can stimulate growth hormone.
It is also well established that:
Growth hormone affects IGF-1, fat metabolism and connective tissue.
But that does not automatically prove:
CJC-1295 No DAC produces major muscle growth, dramatic fat loss, accelerated injury healing, anti-aging, or improved athletic performance.
Those outcomes require their own controlled clinical evidence.
CJC-1295 No DAC is the commercial name commonly used for Modified GRF 1-29, a short-acting synthetic GHRH analogue designed to stimulate endogenous growth hormone secretion.
Its primary research areas include:
Growth hormone secretion
IGF-1
Recovery
Fat metabolism
Body composition
Connective tissue
Sleep-related endocrine function
Age-related GH decline
"CJC-1295 No DAC 10mg" describes the represented total amount of peptide contained in a vial. It should not be interpreted as a recommended 10mg dose.
The most accurate description is:
CJC-1295 No DAC, commonly referring to Modified GRF 1-29, is an experimental short-acting GHRH analogue that stimulates the pituitary growth hormone pathway. Its biological ability to stimulate GH is well grounded in established GHRH physiology, but claims involving substantial muscle growth, fat loss, injury recovery, athletic enhancement, or anti-aging go considerably beyond the available clinical evidence. It is also fundamentally different from long-acting CJC-1295 with DAC, and the two should not be treated as interchangeable compounds.
We do not accept returns or issue refunds for any reason, beside manufacturing defects.
Feel free to contact us if you have any questions or concerns about our Return Policy.
